TF and neoplasm: The evidence of a high expression of tissue factor (TF) on CC surfaces, along with its critical role in promoting tumor growth and progression, and angiogenesis within the TME [28], led to the development of a new ADC, tisotumab-vedotin (TV), which binds TF through a fully humanized mAb linked via a cleavable mc-VC-PABC to the cytotoxic payload monomethyl auristatin E (MMAE), an antimitotic agent which induces G2/M cell cycle arrest, finally leading to cell death [29].